Physician profile
Meagan Moore
NPI 1447388244
$3,935.27
in general payments reported to CMS, 2019-2025
42 companies · $471 in 2025
The $471 reported for 2025 was more than what 78% of providers received nationally.
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $408 · 2020: $341 · 2021: $526 · 2022: $673 · 2023: $1,055 · 2024: $461 · 2025: $471.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,874 · Education: $113.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,874.00 |
| Education | $112.65 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $757.86 | 2019-2024 | |
| Mayne Pharma Commercial LLC | $337.32 | 2019-2025 | |
| Hologic Sales and Service, LLC | $307.76 | 2019-2025 | Aptima, Novasure, Myosure Tissue Removal Device |
| Seagen INC. | $255.07 | 2023 | Tivdak |
| Therapeuticsmd, INC. | $209.54 | 2019-2022 | |
| Organon LLC | $162.47 | 2021-2025 | Nexplanon |
| Astellas Pharma US INC | $146.66 | 2022-2023 | Myrbetriq, Veozah |
| Takeda Pharmaceuticals U.S.A., INC. | $121.75 | 2021 | |
| Astrazeneca Pharmaceuticals Lp | $120.87 | 2024 | Lynparza |
| Dysis Medical, INC. | $107.92 | 2020 | |
| Exeltis, USA INC. | $103.70 | 2024-2025 | Slynd |
| Novo Nordisk INC | $103.66 | 2022-2023 | Ozempic, Rybelsus |
| Sumitomo Pharma America, INC. | $97.95 | 2023-2024 | Myfembree |
| Millicent US INC | $94.59 | 2024 | Intrarosa, Femring |
| Exact Sciences Corporation | $92.05 | 2023-2025 | Cologuard Collection Kit |
Show all 42 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Meagan Moore listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.